Not good. Tobi podhaler sales are plateaued due to the nature of the CF market. There is little to no investment in Arcapta. There is no market for mono LABAs. Seebri and Ultibro have big upsides ex-US. Especially Ultibro. But in the US They will be bid instead of qd which will hurt them. Novartis is looking for a US partner to market them. Xolair for asthma does well but that is Genentech/Roche. Xolair for urticaria is a niche indication with limited sales potential.
Thanks for the response. I may still pursue an opportunity. Current job not stable. Decent pipeline. I hope the division is treated like adults. Is the job a mixture of office and hospital?
You obviously don't work for Resp. Keep you stupid opinions to yourself! Only place in gen Meds where reps are treated with respect!
Oh but I have worked in Resp for well over a decade. But I am not a sales rep so I come from a different perspective.
